Core Insights - Illinois schools are experiencing a significant teacher shortage, with 90% of districts struggling to fill vacancies [2][3] - Kelly Education has filled 5.2 million substitute educator positions during the 2023–24 school year, demonstrating its commitment to supporting educational institutions [2] - The company is launching the Kelly Education Learning Pathways™, a tiered professional learning platform aimed at enhancing the skills of substitute teachers [1][3] Company Initiatives - The Learning Pathways platform offers three levels of training: Essential, Enhanced, and Exemplary, designed to prepare substitute educators effectively [1][3] - The curriculum focuses on key areas such as classroom management, instructional strategies, and student engagement practices to ensure a positive learning environment [7][8] - Additional courses and modules will be available for purchase, allowing educators to further develop their skills [4] Benefits for Schools - The platform provides a customizable, outcome-led curriculum that aids in improving recruitment and retention of substitute teachers [8] - School and district leaders can access a dashboard for performance monitoring and training completion, which helps track return on investment [8] - By implementing effective substitute teacher training, districts can achieve significant time and cost savings while enhancing educational quality [4]

TROY, Mich., April 03, 2025 (GLOBE NEWSWIRE) -- Kelly Education, the nation’s most trusted provider of education talent and workforce solutions, is expanding its commitment to Virginia substitute teacher development with the rollout of Kelly Education Learning Pathways™. This enhanced professional learning platform is designed to equip substitute educators with the skills and confidence they need to succeed in the classroom. The inaugural offering for substitute teachers is available in three levels: Essent ...

TROY, Mich., April 03, 2025 (GLOBE NEWSWIRE) -- Kelly Education, the nation's most trusted provider of education talent and workforce solutions, is expanding its commitment to Kentucky substitute teacher development with the rollout of Kelly Education Learning Pathways™. This enhanced professional learning platform is designed to equip substitute educators with the skills and confidence they need to succeed in the classroom. The inaugural offering for substitute teachers is available in three levels: Essent ...

If you signed up for a Neuralink brain implant, you'll have your skull cut by a brain surgeon before he uses a robot to insert 64 of these tiny threads called electrodes into your brain tissue, which can sense extremely small electrical pulses from your brain cells or stimulate your brain cells so you can see or do or think something. And once those threads are done being inserted, the robot will slide this quartersiz package to cover up your missing skull, plus peel the skin back over. So even though you n ...

CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline of development candidates, today announced the launch of TONIX ONE™, a fully-integrated digital platform designed to help patients better understand and manage their migraine condition. Through a series of strategic partnerships with UpScript Telemedicine, ProModRx, Blink Health and a leading mobile application specializing in d ...

Core Insights - Actelis Networks has received an order from a major North American railway group to support the implementation of its Positive Train Control (PTC) system across challenging track sections [1][3] - PTC systems are designed to enhance rail safety by preventing train-to-train collisions, derailments from excessive speed, and movement through incorrectly positioned switches [2] - Actelis' hybrid-fiber networking technology maximizes bandwidth over existing copper infrastructure while ensuring network diversity through wireless and fiber connections [4] Company Overview - Actelis Networks is a leader in hybrid fiber-copper, cyber-hardened networking solutions for rapid deployment in various applications, including rail, military, and utility sectors [6] - The company's technology is engineered to perform in extreme conditions, providing fast deployment options that avoid significant costs and delays associated with new infrastructure installation [5][8] - Actelis' solutions are designed to maintain network integrity in remote locations and provide uninterrupted connectivity during extreme weather events [8]

Accenture (ACN) Q2 2025 Earnings Call March 20, 2025 08:00 AM ET Company Participants Katie O'Conor - Investor Relations ExecutiveJulie Sweet - Chair and Chief Executive OfficerAngie Park - Chief Financial OfficerJames Faucette - Managing DirectorBryan Bergin - MD - Equity ResearchJonathan Lee - Managing Director, Equity ResearchDarrin Peller - Managing Director Conference Call Participants Jason Kupferberg - Senior Equity Research AnalystTien-tsin Huang - Senior AnalystBryan Keane - Managing Director, Seni ...

图片来源： 20VC with Harry Stebbings Z Highlights Mike Krieger ， Instagram 联合创始人， Anthropic 首席产品官 。在本次节目中，他与 Harry 讨论了 AI 世界中价值的创造和维持，以及 Anthropic 从 DeepSeek 中所习得的。 在 AI 世界中，价值将如何被创造和维持？ Harry Stebbings ： Mike ，伙计，我太激动了。我刚刚散步的时候，几乎听了你去年做的每一集节目。我之前告诉过你，我不想从 " 你是怎么进入科技行 业的 " 这种常规问题开始。我想从一个非常具有挑战性的问题开始，作为今天的风险投资者，我必须确定未来的价值所在。我看着今天的世界，却不知道 答案。所以，我的问题是：当我们展望未来，在接下来的十年里 ——AI 驱动的时代，我们的价值将在哪里创造？ Mike Kriege ： 这是一个很棒的问题，我经常从企业家那里听到它。从最初纯粹做创业公司，到现在经营一家部分帮助新创业公司创建或提升其命运的公 司，我经常被问到：我可以做什么，以避免走入 Antropic 或其他类似实验室的道路？我没有完美的答 ...

Core Insights - The presentation titled "The New Frontier of Longevity Science: Living Well Beyond Your Years" will be led by Dr. Jeffrey A. Lieberman and Dr. David A. Sinclair, focusing on advances in longevity science and the potential to extend human lifespan beyond 100 years while maintaining quality of life [2][3] Group 1: Presentation Details - The event will take place on March 10, 2025, from 2:30 p.m. to 3:30 p.m. at the JW Marriott Austin as part of SXSW 2025's Health & MedTech Track [3] - Following the presentation, Dr. Lieberman will sign copies of his book "Malady of the Mind: Schizophrenia and the Path to Prevention" at the SXSW Bookstore [4] Group 2: Speakers' Backgrounds - Dr. Jeffrey A. Lieberman is a clinical neuroscientist and psychiatrist known for his research on brain disorders and mental illness, with over 800 scientific articles published and cited more than 100,000 times [5] - Dr. David A. Sinclair is a Professor of Genetics at Harvard Medical School, recognized for his research on aging and age-related diseases, with over 180 peer-reviewed articles published and cited over 97,000 times [6][8] Group 3: Key Topics of Discussion - The presentation will cover pivotal advancements in medicine, including human genome sequencing and the discovery of Sirtuin genes, which have made altering the aging process scientifically plausible [7] - It will also discuss holistic strategies and pharmaceutical therapies aimed at enhancing health and targeting aging at the cellular level [7] - Enhanced therapeutic strategies for brain longevity will be explored, including techniques like transcranial magnetic stimulation and psychedelics [7]

Core Insights - Oragenics, Inc. has submitted its Investigator's Brochure (IB) application for the Phase II clinical trial of ONP-002, a novel intranasal neurosteroid aimed at treating mild traumatic brain injury (mTBI) [1][5] - The Phase II study will assess the feasibility, safety, tolerability, and pharmacokinetics of ONP-002 in mTBI patients, with a focus on cognitive and visual motor testing [2][6] Company Overview - Oragenics is a biotechnology company focused on developing nasal delivery systems for pharmaceutical treatments in neurology and infectious diseases, including therapies for mTBI and Niemann Pick Disease Type C [7] Clinical Trial Details - The Phase II trial is randomized, double-blind, and placebo-controlled, enrolling 40 participants, with 20 receiving ONP-002 and 20 receiving a placebo [6] - Participants will receive nine doses over five days, with the first dose administered within 12 hours of injury [6] Medical Context - Mild TBI, or concussion, is a common form of head trauma with no FDA-approved drug therapies currently available, indicating a significant unmet medical need [4]